COMP <GO>
CGEN vs MRK // REVENUE GROWTH (YOY)
Compugen Ltd. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: CGEN 8
— MRK 3
▲ REVENUE GROWTH (YOY) LEADER: CGEN
LAST: $1.98 (-2.94%) • MKT CAP: $193.0M
revenue-growth
161.10%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
revenue-growth
1.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CGEN VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CGEN | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.30% | 74.80% | +12.50 | CGEN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 20.70% | +64.30 | CGEN | /roic <GO> |
| EV/EBITDA & P/E Valuation | 3.2x | 15.3x | -12.10 | CGEN | /valuation <GO> |
| Free Cash Flow Yield | 16.24% | 3.42% | +12.82 | CGEN | /fcf-yield <GO> |
| Operating Margin | 43.10% | 34.30% | +8.80 | CGEN | /operating-margins <GO> |
| Net Profit Margin | 48.60% | 28.10% | +20.50 | CGEN | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 161.10% | 1.30% | +159.80 | CGEN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.19 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.1 | 51.7 | -10.56 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 4.6x | 18.4x | -13.80 | CGEN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $193.0M | $361.02B | -$360.83B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CGEN REV | MRK REV | CGEN GROSS % | MRK GROSS % | CGEN FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $72.8M | $65.01B | 87.3% | 74.8% | $31.3M | $12.36B |
| FY 2024 | $27.9M | $64.17B | 71.5% | 76.3% | $49.5M | $18.10B |
| FY 2023 | $33.5M | $60.12B | — | — | -$35.9M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CGEN // BETA —
MRK // BETA 0.92